The Scientist

» drug development and disease/medicine

Most Recent

image: Techniques for Assessing Genomic Copy Number Variations

Techniques for Assessing Genomic Copy Number Variations

By | October 1, 2016

As the importance of genomic copy number variations for health and disease becomes clearer, researchers are creating new ways to detect these changes in the genome.

0 Comments

image: Genes Linked to Dogs’ Sociability with People

Genes Linked to Dogs’ Sociability with People

By | September 30, 2016

Genetic variants on chromosome 26 appears to play a role in a dog’s tendency to turn to people for help.

0 Comments

image: Broadly Neutralizing Antibodies in HIV Patients

Broadly Neutralizing Antibodies in HIV Patients

By | September 28, 2016

Researchers identify aspects of the patient, the virus, and the infection itself that influence whether a person with HIV will produce broadly neutralizing antibodies.

0 Comments

image: Q&A: From FDA to Industry

Q&A: From FDA to Industry

By | September 27, 2016

Among a subset of US Food and Drug Administration regulators who leave the agency, more than half go to work for pharmaceutical companies, researchers report.

1 Comment

The National Institutes of Health is hosting a two-day conference on how the virus affects infants and children. The take-home message so far: microcephaly is but one of many potential problems for Zika-exposed fetuses.

0 Comments

image: Allergan’s Buying Spree Rolls On

Allergan’s Buying Spree Rolls On

By | September 21, 2016

The Ireland-based pharma company makes a $1.7 billion offer to acquire Tobira Therapeutics, a US firm developing liver disease drugs.

0 Comments

image: Feds Demand More Clinical Trial Reporting

Feds Demand More Clinical Trial Reporting

By | September 19, 2016

Expanded US Health and Human Services rules will require the results of more human studies to be made public.

1 Comment

Scientists estimate the risk to fetuses exposed to the virus in utero.

0 Comments

image: Allergan Set to Buy Vitae

Allergan Set to Buy Vitae

By | September 16, 2016

The Irish drugmaker has made a $639 million dollar offer to buy the US-based biopharma.

0 Comments

Matching the immunological characteristics of donor retinal cells to those of the recipient can reduce the chance of rejection.

0 Comments

Popular Now

  1. Gut Microbes Linked to Neurodegenerative Disease
  2. Top 10 Innovations 2016
    Features Top 10 Innovations 2016

    This year’s list of winners celebrates both large leaps and small (but important) steps in life science technology.

  3. Opinion: WHO’s Silence on Cannabis
  4. Image of the Day: Parting Ways
    Image of the Day Image of the Day: Parting Ways

    The Allen Institute for Cell Science releases the first public collection of human induced pluripotent stem cells that have been fluorescently tagged using CRISPR.

Rockland